Chugai Pharmaceutical Co., Ltd. (CHGCY) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - General industry. The company is headquartered in Tokyo, Japan. The current CEO is Osamu Okuda.
CHGCY has IPO date of 2012-08-03, 5,026 full-time employees, listed on the Other OTC, a market capitalization of $88.77B.
Chugai Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing, and global distribution of innovative medicines. The company maintains a diversified portfolio spanning oncology, osteoporosis, renal diseases, and neurology, with key marketed products including Avastin, Tecentriq, Herceptin, Actemra, and Hemlibra, alongside a robust pipeline of development candidates across multiple therapeutic areas. As a subsidiary of Roche Holding Ltd., Chugai leverages strategic alliances and collaborative research partnerships to advance its drug development initiatives. Founded in 1925 and headquartered in Tokyo, the company combines decades of pharmaceutical expertise with Roche's global resources and capabilities.
